The mystery of human papillomaviruses in carcinogenesis

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 1-4

  Mabruk, Mohamed ^a  

^a UNIVERSITI BRUNEI DARUSSALAM   (Brunei Darussalam)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN E; GLYCOPROTEIN E2; WART VIRUS VACCINE; ONCOPROTEIN;

CANCER RISK; CARCINOGENESIS; DNA REPLICATION; DNA SYNTHESIS; EDITORIAL; HUMAN; IN SITU HYBRIDIZATION; NONHUMAN; PAPILLOMA VIRUS; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; VIRUS INFECTION; WART VIRUS; CELL TRANSFORMATION; NEOPLASM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE;

EID: 38149061158     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.1     Document Type: Editorial

References (38)

1. Chaturvedi AK, Engels EA, Gilbert ES et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J. Natl Cancer Inst. 99(21), 1634-1643 (2007).
2. Sanclemente G, Herrera S, Tyring SK et al. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J. Eur. Acad. Dermatol. Venereol. 21(8), 1054-1060 (2007).
3. O'Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, Mabruk MJ. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J. Clin. Pathol. 54(7), 539-542 (2001).
4. Campisi G, Panzarella V, Giuliani M et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int. J. Oncol. 30(4), 813-823 (2007).
5. Schlecht NF, Burk RD, Adrien L et al. Gene expression profiles in HPV-infected head and neck cancer. J. Pathol. 213(3), 283-293 (2007).
6. Androphy EJ. Molecular biology of human papillomavirus infection and oncogenesis. J. Invest. Dermatol 103(2), 248-256 (1994).
7. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr. Opin. Infect. Dis. 15(2), 101-114 (2002).
8. Icenogle JP, Sathya P, Miller DL, Tucker RA, Rawls WE. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16. Virology 184(1), 101-107 (1991).
9. Bishop B, Dasgupta J, Klein M et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J. Biol. Chem. 282(43), 31803-31811 (2007).
10. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. 16, 504-514 (1997).
11. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69, 7791-7799 (1995).
12. CIP-dependent pathways. EMBO J. 19, 5762-5771 (2000).
13. Gammoh N, Grm HS, Massimi P, Banks L. Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J. Virol. 80(4), 1787-1797 (2006).
14. Grm HS, Massimi P, Gammoh N, Banks L. Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein. Oncogene 24(33), 5149-5164 (2005).
15. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69, 7791-7799 (1995).
16. Stubenrauch F, Straub E, Fertey J, Iftner T. The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins. Int. J. Cancer 15, 121(10), 2284-2292 (2007).
17. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci. 13, 1003-1017 (2008).
18. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell Biol. 13(8), 4918-4927 (1993).
19. Zeng M, Kumar A, Meng G et al. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J. Biol. Chem. 277(47), 45611-45618 (2002).
20. Leverrier S, Bergamaschi D, Ghali L et al. Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis 12(3), 549-560 (2007).
21. Wang PH, Chen GD, Chang H et al. High expression of human telomerase reverse transcriptase in high-grade intraepithelial neoplasia and carcinoma of uterine cervix and its correlation with human papillomavirus infection. Reprod. Sci. 14(4), 338-348 (2007).
22. Hengstermann A, Linares K, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6 mediated degradation of p53 in cervical cancer cells. Proc. Natl Acad. Sci. USA 98, 1218-1223 (2001).
23. Beer-Romero P, Glass S, Rolfe M. Antisense targeting of E6AP elevates p53 in HPV infected cells but not in normal cells. Oncogene 14(5), 595-602 (1997).
24. Bahnassy AA, Zekri AR, Saleh M, Lotayef M, Moneir M, Shawki O. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin. Pathol. 7, 4 (2007).
25. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci. 13, 1003-1017(2008)
26. Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279(24), 25729-25744 (2004).
27. Jones EE, Wells SI. Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr. Mol. Med. 6(7), 795-808 (2006).
28. Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69(10), 6389-6399 (1995).
29. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13(11), 2323-2330 (1996).
30. González Martín A. Molecular biology of cervical cancer. Clin. Transl. Oncol. 9(6), 347-354 (2007).
31. 1/S transition. Oncogene 21(37), 5665-5672 (2002).
32. Caldeira S, Zehbe I, Accardi R et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 77(3), 2195-206 (2003).
33. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than Rb. Mol. Pathol. 54(3), 165-169 (2001).
34. Elbel M, Carl S, Spaderna S, Iftner T. (1997) A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 239(1), 132-149 (1997).
35. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc. Natl Acad. Sci. USA 87(1), 463-467 (1990).
36. Gnanamony M, Peedicayil A, Abraham P. An overview of human papillomaviruses and current vaccine strategies. Indian J. Med. Microbiol. 25(1), 10-17 (2007).
37. American Social Health Association www.ashastd.org
38. Genital HPV Infection: CDC Fact Sheet www.cdc.gov/std/hpv/STDFact-HPV.htm